Capricor Therapeutics Announces Positive 3-Year Efficacy ...
Capricor Therapeutics reported positive 3-year results from the HOPE-2 study of CAP-1002 for Duchenne Muscular Dystrophy, showing benefits in skeletal muscle function and cardiac function stabilization. Results were shared with the FDA, supporting CAP-1002's long-term impact and safety profile.
Related Clinical Trials
Reference News
CAP-1002, an investigational cell therapy by Capricor Therapeutics, aims to improve muscle strength and heart health in Duchenne muscular dystrophy (DMD) patients through intravenous infusion. It uses cardiosphere-derived cells to promote muscle repair, reduce inflammation, and inhibit scarring. Currently in Phase 3 trials, CAP-1002 has shown promise in slowing disease progression and improving cardiac function, with ongoing studies to confirm its efficacy and safety.
Capricor Therapeutics reported positive 3-year results from the HOPE-2 study of CAP-1002 for Duchenne Muscular Dystrophy, showing benefits in skeletal muscle function and cardiac function stabilization. Results were shared with the FDA, supporting CAP-1002's long-term impact and safety profile.
Capricor Therapeutics' CAP-1002 shows sustained benefits in arm and heart function for Duchenne muscular dystrophy (DMD) patients after three years in the HOPE-2 OLE study. The Phase 3 HOPE-3 trial results are anticipated by end of 2024, aiming for FDA approval. CAP-1002, derived from donor heart tissue, has received multiple designations to expedite its development.